The Trump administration finalized a rule on October 13, 2026, using agency directive authority under the Centers for Medicare & Medicaid Services (CMS) to end federal support for gender-affirming care through Medicaid and the Children's Health Insurance Program (CHIP). The rule eliminates federal funding pathways for medical services including hormone therapy, surgical interventions, and mental health support related to gender transition. The mechanism operates by prohibiting CMS reimbursement and directing state Medicaid programs to deny coverage for these treatments, effectively leveraging federal funding conditions to coerce state compliance with the administration's anti-transgender policy.

The rule directly affects transgender children and adolescents enrolled in Medicaid and CHIP—populations that are disproportionately low-income and already face barriers to healthcare access. An estimated 200,000+ transgender youth rely on these programs for medical coverage. The action forces families to choose between discontinuing evidence-based medical care or bearing catastrophic out-of-pocket costs. Children in states with limited alternative funding face complete loss of access to treatments recommended by the American Medical Association, American Academy of Pediatrics, and Endocrine Society. The rule particularly harms rural and economically disadvantaged transgender youth who lack private insurance alternatives.

This action represents a systematic escalation of the administration's assault on transgender rights and federal civil rights protections. It follows the Education Department's Title IX investigation into Smith College for admitting transgender women, the military transgender service ban defended at the appeals court, and the broader pattern of federal agencies abandoning discrimination cases documented across the government. The EEOC's concurrent effort to overturn employment discrimination protections and DOJ's termination of police reform oversight indicate a coordinated dismantling of federal civil rights enforcement. Each action removes legal accountability and federal protections for vulnerable populations, with this healthcare rule specifically targeting minors unable to independently access care.

Multiple legal challenges are pending. Civil rights organizations, medical associations, and state attorneys general have filed suits arguing the rule violates the Administrative Procedure Act by ignoring contrary scientific evidence, violates the Affordable Care Act's non-discrimination protections, and potentially violates equal protection and due process rights. Federal courts have preliminarily blocked similar restrictions in other contexts, though the Supreme Court's conservative majority presents uncertainty. Several states have signaled intent to maintain coverage through alternative state funding mechanisms, though this creates a patchwork leaving many children without access.

Reversal would require either judicial invalidation or congressional action restoring CMS authority to cover gender-affirming care and explicitly prohibiting discrimination in Medicaid and CHIP coverage decisions based on gender identity. Medical evidence review and reinstatement of coverage aligned with major medical society guidelines would be necessary to restore access for affected youth.